COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03758417
Previous Study | Return to List | Next Study

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03758417
Recruitment Status : Active, not recruiting
First Posted : November 29, 2018
Last Update Posted : September 9, 2020
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Nanjing Legend Biotech Co.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 25, 2020
Estimated Study Completion Date : September 26, 2022